

# Paolo Macor

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8655104/publications.pdf>

Version: 2024-02-01

61  
papers

2,544  
citations

201385

27  
h-index

197535

49  
g-index

65  
all docs

65  
docs citations

65  
times ranked

3375  
citing authors

#	ARTICLE	IF	CITATIONS
1	Thrombus formation induced by antibodies to Î²2-glycoprotein I is complement dependent and requires a priming factor. <i>Blood</i> , 2005, 106, 2340-2346.	0.6	324
2	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. <i>Blood</i> , 2014, 124, 1715-1726.	0.6	288
3	Complement in human diseases: Lessons from complement deficiencies. <i>Molecular Immunology</i> , 2009, 46, 2774-2783.	1.0	250
4	<i>In vivo</i> Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab. <i>Cancer Research</i> , 2007, 67, 10556-10563.	0.4	141
5	A non-“complement-fixing antibody to Î²2 glycoprotein I as a novel therapy for antiphospholipid syndrome. <i>Blood</i> , 2014, 123, 3478-3487.	0.6	120
6	The Development of Atypical Hemolytic Uremic Syndrome Depends on Complement C5. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 137-145.	3.0	105
7	Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. <i>European Journal of Immunology</i> , 2005, 35, 2175-2183.	1.6	92
8	Complement as effector system in cancer immunotherapy. <i>Immunology Letters</i> , 2007, 111, 6-13.	1.1	72
9	Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. <i>Blood</i> , 2016, 127, 365-367.	0.6	67
10	Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. <i>Frontiers in Immunology</i> , 2018, 9, 1388.	2.2	51
11	Cubosomes stabilized by a polyphosphoester-analog of Pluronic F127 with reduced cytotoxicity. <i>Journal of Colloid and Interface Science</i> , 2020, 580, 286-297.	5.0	49
12	C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function. <i>Blood</i> , 2009, 113, 3640-3648.	0.6	44
13	Cubosomes for <i>in vivo</i> fluorescence lifetime imaging. <i>Nanotechnology</i> , 2017, 28, 055102.	1.3	44
14	Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients. <i>Biomedicines</i> , 2021, 9, 1003.	1.4	44
15	The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: <i>in vitro</i> and <i>in vivo</i> studies. <i>European Journal of Immunology</i> , 2002, 32, 2773-2782.	1.6	40
16	New insight into antiphospholipid syndrome: antibodies to Î²2glycoprotein I-domain 5 fail to induce thrombi in rats. <i>Haematologica</i> , 2019, 104, 819-826.	1.7	40
17	Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. <i>Arthritis and Rheumatism</i> , 2012, 64, 2559-2567.	6.7	39
18	Simple scale-up of recombinant antibody production using an UCOE containing vector. <i>New Biotechnology</i> , 2012, 29, 477-484.	2.4	37

#	ARTICLE	IF	CITATIONS
19	Complement Activated by Chimeric Anti-Folate Receptor Antibodies Is an Efficient Effector System to Control Ovarian Carcinoma. <i>Cancer Research</i> , 2006, 66, 3876-3883.	0.4	36
20	New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles. <i>PLoS ONE</i> , 2013, 8, e74216.	1.1	34
21	Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2019, 103, 102288.	3.0	33
22	The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target. <i>Journal of Oncology</i> , 2020, 2020, 1-15.	0.6	33
23	Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. <i>Arthritis Research and Therapy</i> , 2016, 18, 111.	1.6	32
24	Complement as a Biological Tool to Control Tumor Growth. <i>Frontiers in Immunology</i> , 2018, 9, 2203.	2.2	31
25	Critical Role and Therapeutic Control of the Lectin Pathway of Complement Activation in an Abortion-Prone Mouse Mating. <i>Journal of Immunology</i> , 2015, 195, 5602-5607.	0.4	30
26	Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats. <i>Arthritis and Rheumatism</i> , 2007, 56, 1187-1197.	6.7	29
27	In Vivo Biodistribution and Lifetime Analysis of Cy5.5-Conjugated Rituximab in Mice Bearing Lymphoid Tumor Xenograft Using Time-Domain Near-Infrared Optical Imaging. <i>Molecular Imaging</i> , 2008, 7, 7290.2008.00028.	0.7	29
28	Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies. <i>International Journal of Nanomedicine</i> , 2015, 10, 4099.	3.3	26
29	Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab. <i>Autoimmunity Reviews</i> , 2019, 18, 561-563.	2.5	25
30	Posttransplant Ischemia-Reperfusion Injury In Transplanted Heart Is Prevented By A Minibody to the Fifth Component of Complement. <i>Transplantation</i> , 2008, 86, 1445-1451.	0.5	24
31	Prevention of Arthritis by Locally Synthesized Recombinant Antibody Neutralizing Complement Component C5. <i>PLoS ONE</i> , 2013, 8, e58696.	1.1	24
32	Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2014, 7, 79.	6.9	22
33	An Update on the Xenograft and Mouse Models Suitable for Investigating New Therapeutic Compounds for the Treatment of B-Cell Malignancies. <i>Current Pharmaceutical Design</i> , 2008, 14, 2023-2039.	0.9	20
34	Targeted Delivery of Neutralizing Anti-C5 Antibody to Renal Endothelium Prevents Complement-Dependent Tissue Damage. <i>Frontiers in Immunology</i> , 2017, 8, 1093.	2.2	20
35	The J-elongated conformation of Î²2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome. <i>Journal of Biological Chemistry</i> , 2020, 295, 10794-10806.	1.6	20
36	Phage Display Technology for Human Monoclonal Antibodies. <i>Methods in Molecular Biology</i> , 2014, 1060, 277-295.	0.4	19

#	ARTICLE	IF	CITATIONS
37	Mutations in the 3' untranslated region of <i>NOTCH1</i> are associated with low CD20 expression levels chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e305-e309.	1.7	18
38	A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. <i>Nano Research</i> , 2016, 9, 537-548.	5.8	17
39	Humoral immunotherapy of multiple myeloma: perspectives and perplexities. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 863-873.	1.4	16
40	Complement Activation and Thrombin Generation by MBL Bound to $\beta$ 2-Glycoprotein I. <i>Journal of Immunology</i> , 2020, 205, 1385-1392.	0.4	16
41	Complement system and phagocytosis in a colonial protochordate. <i>Developmental and Comparative Immunology</i> , 2020, 103, 103530.	1.0	14
42	High fecal calprotectin levels are associated with SARS-CoV-2 intestinal shedding in COVID-19 patients: A proof-of-concept study. <i>World Journal of Gastroenterology</i> , 2021, 27, 3130-3137.	1.4	14
43	In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. <i>Molecular Imaging</i> , 2008, 7, 272-82.	0.7	14
44	Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 3274-3288.	0.8	13
45	Effects of eEF1A1 targeting by aptamer/siRNA in chronic lymphocytic leukaemia cells. <i>International Journal of Pharmaceutics</i> , 2020, 574, 118895.	2.6	12
46	An allosteric redox switch in domain V of $\beta$ 2-glycoprotein I controls membrane binding and anti-domain I autoantibody recognition. <i>Journal of Biological Chemistry</i> , 2021, 297, 100890.	1.6	10
47	Invasive meningococcal disease in three siblings with hereditary deficiency of the 8th component of complement: evidence for the importance of an early diagnosis. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 64.	1.2	9
48	Nanoparticles-Based Oligonucleotides Delivery in Cancer: Role of Zebrafish as Animal Model. <i>Pharmaceutics</i> , 2021, 13, 1106.	2.0	7
49	Exploratory Study on the Effects of Biodegradable Nanoparticles with Drugs on Malignant B Cells and on a Human/Mouse Model of Burkitt Lymphoma. <i>Current Clinical Pharmacology</i> , 2010, 5, 246-250.	0.2	6
50	Meniscal Ossicles as micro-CT Imaging Biomarker in a Rodent Model of Antigen-Induced Arthritis: a Synchrotron-Based X-ray Pilot Study. <i>Scientific Reports</i> , 2017, 7, 7544.	1.6	6
51	The Inflammatory Feed-Forward Loop Triggered by the Complement Component C3 as a Potential Target in Endometriosis. <i>Frontiers in Immunology</i> , 2021, 12, 693118.	2.2	5
52	Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. <i>Journal of Autoimmunity</i> , 2021, 124, 102728.	3.0	5
53	Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome. <i>Blood</i> , 2021, 137, 2989-2992.	0.6	4
54	Constitutive PSGL-1 Correlates with CD30 and TCR Pathways and Represents a Potential Target for Immunotherapy in Anaplastic Large T-Cell Lymphoma. <i>Cancers</i> , 2021, 13, 2958.	1.7	4

#	ARTICLE	IF	CITATIONS
55	The terminal complement pathway is activated in septic but not in aseptic shoulder revision arthroplasties. <i>Journal of Shoulder and Elbow Surgery</i> , 2018, 27, 1837-1844.	1.2	3
56	The complement system at the feto-maternal interface: friend or foe?. <i>American Journal of Reproductive Immunology</i> , 2002, 48, 142-143.	1.2	0
57	New advances in chronic lymphocytic leukemia treatment: Biodegradable ZnO hybrid cluster nanoparticle as antineoplastic agents. , 2019, , 409-430.		0
58	Hereditary Deficiency of the Second Component of Complement: Early Diagnosis and 21-Year Follow-Up of a Family. <i>Medicina (Lithuania)</i> , 2020, 56, 120.	0.8	0
59	New Therapeutic Approach for the Treatment of B-Cell Disorders Using Chlorambucil/Hydroxychloroquine-Loaded AntiCD20 Nanoparticles. <i>Blood</i> , 2012, 120, 158-158.	0.6	0
60	Targeted Nanoparticles for the Delivery of Antagomir17: New Approach for the Treatment of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 5293-5293.	0.6	0
61	Mutations at 3' Untranslated Region (3'UTR) of NOTCH1 Are Associated with Low CD20 Expression Levels in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 306-306.	0.6	0